Moderna has rallied ~23%, but I maintain a 'Sell' and 'market underperform' rating due to deteriorating fundamentals. MRNA’s recent rally is driven by improved liquidity, cost discipline, and a $1.5 ...

Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 4% in the morning session after the company announced it would receive up to $54.3 million in funding from the Coalition for Epidemic ...

Moderna has tapped Swedish long-acting drug formulation company Nanexa to improve the delivery of up to five injectable therapies. The heavily back-loaded deal will see Moderna hand over just $3 ...

Marruecos ha logrado que la UNESCO reconozca el caftán como parte del Patrimonio Cultural Inmaterial. La decisión se ha tomado este miércoles en la reunión que la organización ha celebrado en la India ...

Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 6.4% in the afternoon session after a major long-term study from France indicated that its COVID-19 vaccine was safe and effective. The ...

Moderna, an mRNA specialist known for its COVID-19 vaccine Spikevax, is winding down development of three clinical mRNA programs, including two investigational vaccines for infectious diseases. The ...

Alex Hogan is STAT’s senior multimedia producer and host of STATus Report, STAT’s weekly video series. You can follow him on Bluesky. The story of the biotech company Moderna almost reads like a ...

Moderna's decision not to diversify outside of COVID has hurt its business substantially. The company is still generating COVID revenue, but it's insufficient to cover its operating expenses. It's ...

Massachusetts-based Moderna, one of the companies at the forefront of developing a vaccine during the COVID pandemic, announced Thursday that it will lay off about 10% of its workforce. Moderna CEO ...

Biotech giant Moderna announced it will lay off 10% of its workforce in a move CEO Stéphane Bancel called “a difficult decision but necessary step forward,” in an internal memo sent to employees on ...

An mRNA-based seasonal flu vaccine from Moderna was 27 percent more effective at preventing influenza infections than a standard flu shot, the company announced this week. Moderna noted that the new ...

Jefferies analysts said the approval was largely expected and an “incremental positive” for Moderna amid questions about the FDA’s attitude toward mRNA and COVID-19 vaccines that have investors ...